Quality Assessment: Consistent Financial Strength and Operational Excellence
CARE Ratings continues to demonstrate strong operational performance, highlighted by its net-debt free status and a remarkable run of positive quarterly results. The company has reported positive earnings for 11 consecutive quarters, underscoring its resilience and consistent profitability. The return on capital employed (ROCE) for the half-year ended FY25-26 stands at an impressive 24.81%, signalling efficient utilisation of capital resources.
Profit before tax (PBT) excluding other income for the latest quarter reached ₹56.30 crores, reflecting a robust growth rate of 28.77% year-on-year. Similarly, the profit after tax (PAT) surged to ₹52.83 crores, marking a 24.0% increase compared to the previous year. These figures highlight the company’s ability to generate strong earnings growth, which is a key factor in the upgrade of its quality grade.
Institutional investors hold a significant 54.99% stake in CARE Ratings, indicating strong confidence from sophisticated market participants who typically conduct thorough fundamental analysis before committing capital. This institutional backing adds credibility to the company’s quality profile and supports the positive outlook.
Valuation: Premium Pricing Amidst Growth Prospects
Despite the positive financial trajectory, CARE Ratings carries a relatively expensive valuation. The stock trades at a price-to-book (P/B) ratio of 5.6, which is notably higher than the average historical valuations of its peers in the capital markets sector. This premium valuation reflects investor optimism but also introduces a degree of risk if growth expectations are not met.
The company’s return on equity (ROE) stands at 18.4%, which is healthy but not exceptional enough to fully justify the elevated valuation. Furthermore, the price-to-earnings-to-growth (PEG) ratio is 1.3, suggesting that the stock is moderately priced relative to its earnings growth rate. While the PEG ratio indicates some balance between price and growth, investors should remain cautious given the high P/B multiple.
Long-term sales growth has been modest, with net sales increasing at an annualised rate of 13.75% over the past five years, and operating profit growing at 15.76% annually. These growth rates, while respectable, may not fully support the current valuation premium, which is a factor that analysts have considered in their balanced rating upgrade.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Financial Trend: Sustained Earnings Growth and Profitability
The financial trend for CARE Ratings remains positive, supported by consistent quarterly earnings growth and a net-debt free balance sheet. The company’s profitability metrics have improved steadily, with PAT growth of 24.0% in the latest quarter and PBT growth of 28.77%. This sustained earnings momentum has been a key driver behind the upgrade in the financial trend rating.
Comparing stock returns with the benchmark Sensex reveals a strong relative performance over longer periods. Year-to-date, CARE Ratings has delivered a 7.99% return, outperforming the Sensex’s negative 10.36% return. Over three and five years, the stock has generated exceptional returns of 133.64% and 142.98% respectively, far exceeding the Sensex’s 14.56% and 44.20% gains. This long-term outperformance underscores the company’s solid financial footing and growth potential.
However, the one-year return of -6.56% slightly lags the Sensex’s -7.66%, reflecting some short-term volatility despite rising profits. This divergence between price performance and earnings growth is reflected in the PEG ratio and valuation concerns, which temper the overall financial trend outlook.
Technicals: Bullish Momentum Fuels Upgrade
The most significant catalyst for the rating upgrade has been the marked improvement in technical indicators. CARE Ratings’ technical grade has shifted from mildly bullish to bullish, signalling stronger momentum and positive market sentiment.
Key technical signals include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart, supported by bullish Bollinger Bands on both weekly and monthly timeframes. The daily moving averages also confirm a bullish trend, reinforcing the positive price momentum. The Know Sure Thing (KST) indicator is bullish on the weekly chart, although mildly bearish on the monthly, indicating some caution over longer horizons.
Other technical metrics such as On-Balance Volume (OBV) are bullish on both weekly and monthly charts, suggesting strong buying interest. The Dow Theory assessment is mildly bullish weekly but shows no clear trend monthly, reflecting a cautiously optimistic technical outlook.
CARE Ratings’ stock price has recently risen to ₹1,728.70, up 3.26% on the day, with a 52-week high of ₹1,856.65 and a low of ₹1,393.95. The stock’s recent weekly return of 3.39% outpaces the Sensex’s decline of 1.03%, further validating the bullish technical stance.
Want to dive deeper on CARE Ratings Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Balancing Risks and Opportunities
While the upgrade to a Buy rating reflects CARE Ratings’ improved fundamentals and technical outlook, investors should remain mindful of certain risks. The company’s long-term growth in net sales and operating profit, at 13.75% and 15.76% annually respectively, is moderate and may not fully justify the current premium valuation. Additionally, the stock’s one-year negative return despite rising profits suggests some near-term volatility.
Valuation remains a key concern, with the stock trading at a high price-to-book ratio and a PEG ratio above 1, indicating that expectations are already priced in to some extent. Investors should weigh these factors against the company’s strong financial health, net-debt free status, and bullish technical signals when considering their investment decisions.
Overall, the upgrade to a Buy rating by MarketsMOJO, with a Mojo Score of 71.0, reflects a balanced view that favours CARE Ratings’ quality and momentum while acknowledging valuation risks. The company remains a compelling small-cap opportunity within the capital markets sector, particularly for investors seeking exposure to a fundamentally sound and technically strong stock.
Summary of Ratings and Scores
CARE Ratings Ltd’s current Mojo Grade is Buy, upgraded from Hold on 23 July 2026. The stock is classified as a small-cap with a market capitalisation grade reflecting this status. The technical grade improvement from mildly bullish to bullish was the primary driver of the rating change, supported by strong financial trends and quality metrics. The company’s stock price has shown resilience and outperformance relative to the Sensex over multiple timeframes, reinforcing the positive outlook.
Conclusion
The upgrade of CARE Ratings Ltd to a Buy rating is a testament to its sustained financial performance, strong institutional backing, and improving technical momentum. While valuation concerns warrant caution, the company’s consistent earnings growth, net-debt free balance sheet, and bullish technical indicators provide a solid foundation for future appreciation. Investors looking for a fundamentally robust and technically sound small-cap stock in the capital markets sector may find CARE Ratings an attractive addition to their portfolios.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
